High frequency of loss of heterozygosity at 11p15 and IGF2 overexpression are not related to clinical outcome in childhood adrenocortical tumors positive for the R337H TP53 mutation.
A germline TP53 R337H mutation is present in childhood adrenocortical tumors (ACT) from southern Brazil. Other genetic alterations are also frequently found in these tumors. This study was designed to assess whether alterations of the 11p15 region exist in childhood ACT, accounting for IGF2 overexpression in these tumors, and how they are related to clinical outcome. Tumor DNA of 12 children with ACT (4 adenomas and 8 carcinomas) and from the blood of their parents was analyzed. All patients showed 11p15 loss of heterozygosity (LOH) in the tumor. In contrast to the single case of paternal LOH, IGF2 was overexpressed in tumors with maternal allele loss. Our data show that 11p15 LOH is a widespread finding in childhood ACT not related with malignancy, contrary to adult ACT. Alterations in the expression of other genes in the same region (e.g., CDKN1C) may contribute to ACT tumorigenesis.
Rosati
Roberto
R
Instituto de Pesquisa Pelé Pequeno Principe, Curitiba, Av. Silva Jardim, Paraná, Brazil.
Cerrato
Flavia
F
Doghman
Mabrouka
M
Pianovski
Mara A D
MA
Parise
Guilherme A
GA
Custódio
Gislaine
G
Zambetti
Gerard P
GP
Ribeiro
Raul C
RC
Riccio
Andrea
A
Figueiredo
Bonald C
BC
Lalli
Enzo
E
D000236:Adenoma / Q000453:epidemiology / Q000235:genetics* / Q000401:mortality; D000293:Adolescent; D000306:Adrenal Cortex Neoplasms / Q000453:epidemiology / Q000235:genetics* / Q000401:mortality; D000367:Age Factors; D019943:Amino Acid Substitution; D001938:Brazil / Q000453:epidemiology; D002277:Carcinoma / Q000453:epidemiology / Q000235:genetics* / Q000401:mortality; D002648:Child; D002675:Child, Preschool; D002880:Chromosomes, Human, Pair 11 / Q000235:genetics* / Q000648:ultrastructure; D019175:DNA Methylation; D015972:Gene Expression Regulation, Neoplastic; D016158:Genes, p53 / Q000235:genetics*; D018392:Genomic Imprinting; D018095:Germ-Line Mutation; D006801:Humans; D007223:Infant; D007335:Insulin-Like Growth Factor II / Q000096:biosynthesis / Q000235:genetics*; D019656:Loss of Heterozygosity; D020125:Mutation, Missense; D009363:Neoplasm Proteins / Q000096:biosynthesis / Q000235:genetics*; D009386:Neoplastic Syndromes, Hereditary / Q000453:epidemiology / Q000235:genetics* / Q000401:mortality; D017354:Point Mutation; D016896:Treatment Outcome
D009363:Neoplasm Proteins; D007335:Insulin-Like Growth Factor II
J Natl Cancer Inst. 1994 Nov 16;86(22):1707-10
7966399
N Engl J Med. 2007 Jun 7;356(23):2372-80
17554118
Am J Hum Genet. 1997 Aug;61(2):295-303
9311733
Endocrinology. 1999 Apr;140(4):1537-43
10098485
Am J Hum Genet. 1999 Oct;65(4):995-1006
10486318
J Clin Oncol. 2004 Mar 1;22(5):838-45
14990639
Am J Surg Pathol. 2003 Jul;27(7):867-81
12826878
Mol Endocrinol. 2007 Dec;21(12):2968-87
17761949
J Clin Endocrinol Metab. 2000 May;85(5):2048-56
10843195
Cancer Res. 2007 Jan 15;67(2):600-8
17234769
Endocr Rev. 1997 Jun;18(3):378-403
9183569
Nat Genet. 2004 Sep;36(9):958-60
15314640
Hum Mol Genet. 2003 Apr 1;12 Spec No 1:R61-8
12668598
J Clin Endocrinol Metab. 2002 Dec;87(12):5367-84
12466322
J Clin Endocrinol Metab. 1997 Aug;82(8):2559-65
9253334
J Clin Endocrinol Metab. 2005 Feb;90(2):615-9
15546904
Nature. 1997 May 8;387(6629):151-8
9144284
Hum Mol Genet. 2007 Feb 1;16(3):254-64
17158821
Nat Genet. 1996 Oct;14(2):171-3
8841187
J Med Genet. 2004 May;41(5):354-9
15121773
Eur J Cancer. 2006 May;42(8):1040-3
16574405
Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):9330-5
11481490
Nat Struct Biol. 2002 Jan;9(1):12-6
11753428
Am J Pathol. 2003 Feb;162(2):521-31
12547710